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Abstract Tables Discussion
Dravet Syndrome is a rare, early-onset pediatric epilepsy characterized by prolonged, 
treatment-resistant seizures and a spectrum of neurodevelopmental delays (2). It is a 
sodium channelopathy, most commonly caused by a mutation in the alpha-1 subunit of 
voltage-gated sodium channel gene (SCN1A) (2). Dravet Syndrome  is estimated to 
affect 1 in 15,700 - 40,000 live births (2), with onset of seizures typically between 1-
18 months old. Diagnosis  and management is challenging as there is lack of universal 
diagnostic guidelines and treatment protocols. Furthermore, seizures associated with 
Dravet Syndrome are typically refractory to medical management and routinely 
present in status epileptics. The mainstay treatment algorithm for status epilepticus, 
being Sodium Channel blocking agents, are contraindicated in treating patients with 
Dravet Syndrome. It is essential for Emergency Medicine Physicians to not only 
recognize Dravet Syndrome, but to be familiar with appropriate treatment and 
management of these patients presenting in status epilepticus. This disease carries 
high morbidity and mortality, making quick intervention a necessity for these patients. 
Dravet Syndrome, formerly known as ”severe myoclonic epilepsy of infancy” is a rare form of 
infantile infantile-onset epilepsy syndrome characterized by prolonged, treatment-resistant 
seizures and a spectrum of neurodevelopmental delays after seizure onset (2). Reports from recent 
studies suggest Dravet Syndrome may account for 3-7% of epilepsy cases in patients whom initial 
seizure presentation occurs by 3 years old (2).  Pathophysiology of disease is poorly understood, 
but believed to be due to a mutation in alpha-1 subunit of voltage-gated sodium channel gene 
(SCN1A) (2). This causes impaired action firing in GABAergic interneurons, leading to  
dysfunction of inhibitory interneurons (disinhibition), thus creating a hyperexcitable state. 
Dravet Syndrome is primarily identified by key clinical features (Figure 1), and further supported 
by genetic testing, although it is not necessary for diagnosis. Criteria to help guide diagnostic, 
treatment, and management standards was recently created by The North American Consensus 
Panel. Seizures associated with DS are typically resistant to pharmacologic therapy. Complete 
seizure control is unlikely as most patients require 2-3 anti-epileptics to achieve optimal control.
The importance of ED recognition of Dravet syndrome is that treatment regiment is unique, in 
that typical treatment algorithms for status epilepticus is contraindicated in DS (ie Na channel 
blocking agents). For ED physicians, initial diagnosis is unlikely to take place in the Emergency 
Room, although, you may be treating young infants on initial seizure presentation.  It is important 
to work with local neurologist and pediatric specialists  to individual seizure protocol for when 
these patients presents to the local ED. It is equally important for parents of affected patients to 
have a home regiment of rescue medications (rectal diazepam, Buccal/nasal midazolam). 
Case Presentation Conclusion
• 21moF with known Dravet Syndrome presented to the ED for witnessed unilateral 
convulsive seizure. Symptoms started 20 minutes prior to ED arrival and were 
continuous since onset. She was given 2 doses of Diastat 5mg PR at home without 
response. Patient was at baseline prior to symptom onset, without fever, recent 
illness, vaccinations, or photic stimuli. She has been compliant with all prescribed 
anti-epileptics. Mother provided ED staff with a list of anti-epileptics she was 
unable to receive, that was provided by patients Neurologist. 
• On arrival to the ED, Initial vital signs: T 36.7 °C (rectal),HR 159 bmp, RR 18, 
SpO2 82-85% RA, POC glucose 130. Patient was unresponsive, with focal 
hemiclonic seizure activity. Initial ED interventions: ABC’s, IV established, 
supplemental oxygen via blow-by nasal cannula, 20cc/kg IVF bolus infused. Patient 
was given 0.2mg/kg Versed IM without response. She was intubated with RSI for 
airway protection given low GCS and respiratory failure with hypoventilation. CBC, 
BMP, magnesium, urinalysis all within normal limits
• Therapeutic Interventions used in ED with successful termination of status 
epilepticus: IV Benzodiazepine, Levetiracetam, Phenobarbital, continuous infusion 
of midazolam
• Total seizure lasted approximately 60 minutes. She was transferred from the ED to a 
tertiary care PICU for escalation of care. Patient was extubated on hospital day 2. 
She regained full neurologic recovery to baseline mental status. Remainder of 
hospital workup was unremarkable.
• Patient was discharged on an increased dose of Keppra and recommendation for a 
secondary antiepileptic. Addition of Midazolam was added to Diazepam for home 
abortive medications. 
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• Dravet syndrome is rare with high frequency of refractory status epileptics
• Disease carries high morbidity and mortality
• It is important for ED physicians to be familiar with disease in order to appropriately 
treat and avoid poor patient outcomes with use of exacerbating anti-epileptics
• Universal guidelines on in-hospital management is yet to be established. Although strong 
consensus that swift elimination of prolonged seizures or status epileptics is among the 
highest priorities in treatment. 
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• IV benzodiazepine x 2
• 0.1mg/kg = 1mg IV Ativan) (0.2mg/kg versed)
• IV Levetiracetam
• 500 mg IV
• IV Phenobarbital
• 20cc/kg IV load
• Midazolam continuous infusion
• 0.2 mg/kg/hr
Figure 2. Our ED Management of Status Epilepticus with seizure resolution
Figure 1. Clinical Features of Dravet Syndrome
IV Benzodiazepine 
*may repeat for 2nd dose
IV Valproic Acid         
*If already therapeutic as home medication then 
skip to 3. 
IV Levtiracetam
Midazolam continuous infusion
IV Barbiturates
Figure 3. Current treatment algorithm for status epileptics in Dravet Syndrome patients 
Figure 4. Maintenance Treatment Algorithm 
AVOID sodium channel anti-epileptics 
as they exacerbate seizures
phenytoin, fosphenytoin, lamotrigine, 
carbamazepine, oxcarbazepine
